SCHEMBL8557296

SCHEMBL8557296

O=C(NCC1CCN(CC2COc3ccc4[nH]ccc4c3O2)CC1)c1cccnc1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.50
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50
HTR1A P08908 6/20 0.49
DRD2 P14416 6/20 0.49
CACNA1I Q9P0X4 1/20 0.42
HTR2A P28223 2/20 0.41
HTR2C P28335 2/20 0.41
HTR2B P41595 2/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
ACHE P22303 2/20 0.40
GSK3B P49841 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7468004 0.89 ADRA2A (0.52) ADRA2AADRA2BADRA2CHTR1ADRD2
SCHEMBL7475056 0.86 HTR1A (0.54) ADRA2AADRA2BADRA2CHTR1ADRD2
SCHEMBL7470011 0.86 ADRA2A (0.48) ADRA2AADRA2BADRA2CHTR1ADRD2
SCHEMBL7467112 0.86 HTR1A (0.51) HTR1ADRD2HTR2AHTR2CHTR2B
SCHEMBL7467130 0.86 HTR1A (0.51) HTR1ADRD2HTR2AHTR2CHTR2B
SCHEMBL7460328 0.86 HTR1A (0.52) ADRA2AADRA2BADRA2CHTR1ADRD2
SCHEMBL7475366 0.86 HTR1A (0.54) ADRA2AADRA2BADRA2CHTR1ADRD2
SCHEMBL7467649 0.85 HTR1A (0.48) ADRA2AADRA2BADRA2CHTR1ADRD2
SCHEMBL7469846 0.85 HTR1A (0.48) ADRA2AADRA2BADRA2CHTR1ADRD2
SCHEMBL7465125 0.85 HTR1A (0.52) ADRA2AADRA2BADRA2CHTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0876372-A1 HETEROARYLCARBOXAMIDE DERIVATIVES KNOLL AKTIENGESELLSCHAFT (DE) 1998-11-11 EP disclosed
WO-1997023485-A1 HETEROARYLCARBOXAMIDE DERIVATIVES KNOLL AKTIENGESELLSCHAFT (DE) 1997-07-03 WO disclosed